Bortezomib Completed Phase 3 Trials for Multiple Myeloma (MM) Diagnostic

IndicationsStatusPurposePhase
CompletedDiagnostic3
clinicaltrials.gov IdentifierTitleDrugs
NCT00093028Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II